CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Curis, Inc. (NASDAQ:CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that the Company will release its second quarter financial results on Tuesday, October 28, 2008 before the market opens. The Company will also hold a conference call on the same day at 10:00 A.M. Eastern time to discuss: (i) its Hedgehog antagonist program under collaboration with Genentech, (ii) CUDC-101, CUDC-305 and other proprietary targeted cancer programs, (iii) its financial results as of and for the three- and nine-month periods ended September 30, 2008, and (iv) additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (800) 591-6945 from the United States or Canada or (617) 614-4911 from other locations, shortly before 10:00 A.M. EDT. The conference ID number is 30630167. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EDT, Tuesday, November 11, 2008. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 35904101.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
Source: Curis, Inc.